Association of tricuspid regurgitation with clinical and echocardiographic outcomes after percutaneous mitral valve repair with the MitraClip System: 30-day and 12-month follow-up from the GRASP Registry

Abstract

Although PMVR with MitraClip led to improvement in MR, TR, and NYHA functional class in patients with baseline moderate/severe TR, the primary safety endpoint at 30-day was impaired, while moderate/severe TR independently predicted death and re-hospitalization for heart failure at 12-month.

Effect of advanced chronic kidney disease in clinical and echocardiographic outcomes of patients treated with MitraClip system

“…These findings may be related to procedural, echocardiographic or patient characteristics. A handful of publications have focused on predictors of outcome following MitraClip [11][12][13][14][15][16]. Regarding procedural issues, both the inability to place a clip and the degree of residual MR left have been linked to a worse outcome [11,14,15].…”

“…However, in spite of this documented benefit, there is still a relevant proportion of patients experiencing adverse events in the follow-up. Likewise, few studies have focused on predictors of clinical adverse events after the MitraClip implantation [11][12][13][14][15][16]. Chronic kidney disease (CKD) has been shown to impact negatively the prognosis of patients diagnosed with heart failure, coronary artery or valvular heart disease, and in those undergoing cardiac interventions [17].…”

Transcatheter Valve-in-Valve Implantation for Failing Bioprosthetic Triscupid Valves

“…13,14 Post-TAVR and post-MitraClip patients with significant residual tricuspid regurgitation following these procedures have a poorer prognosis. 15,16 A study from the Society of Thoracic Surgeons Database reported that 54 375 patients underwent tricuspid valve surgery in the United States between 2000 and 2010 (≈5400 per year) 17 despite an estimated 1.6 million patients experiencing moderate-tosevere tricuspid regurgitation. 18 The only class I indication for tricuspid valve intervention according to the current guidelines 5 is at the time of left valve surgery.…”

Current Status and Clinical Development of Transcatheter Approaches for Severe Mitral Regurgitation

“…However, baseline moderate/severe TR remained an independent predictor for death and rehospitalization for heart failure at 12 months. 30 Patients from the initial experiences, as well as the ones included in the randomized controlled trial, however, had to fulfill strict echocardiographic criteria to be considered suitable for MitraClip therapy, which largely limited its indications.…”